Drugs / MSC exosomes
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05523011 | Mar → Apr 2022 | psoriasis | Paracrine Therapeutics Dermatology Pte. Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04798716 | Sep 2023 → Sep 2024 | COVID-19, acute respiratory distress syndrome | AVEM HealthCare | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02138331 | Apr → Jul 2014 | type 1 diabetes mellitus | General Committee of Teaching Hospitals and Institutes, Egypt | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSC-exosomes | “100 µg MSC exosomes/g ointment” NCT05523011 ↗ |
| Modality | Other / unclassified | “cell free umbilical cord-blood derived MSC microvesicles” NCT02138331 ↗ |
| Route | Intravenous | “intravenous infusion of cell free umbilical cord-blood derived MSC microvesicles” NCT02138331 ↗ |